Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations

v3.24.2.u1
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Operating expenses:        
Research and development $ 1,361 $ 3,027 $ 3,752 $ 4,242
Research and development – licenses acquired 0 0 0 4,230
General and administrative 1,462 896 2,778 1,880
Loss from operations (2,823) (3,923) (6,530) (10,352)
Other income (expense):        
Interest income 52 57 100 94
Financing costs – warrant liabilities 0 0 0 (332)
Loss on settlement of common stock warrant liabilities (185) 0 (759) 0
Change in fair value of warrant liabilities 255 (150) 139 (1,028)
Total other income (expense) 122 (93) (520) (1,266)
Net loss (2,701) (4,016) (7,050) (11,618)
Net loss attributable to non-controlling interests (9) (9) (18) (75)
Net loss attributable to Avenue (2,692) (4,007) (7,032) (11,543)
Net loss attributable to common stockholders $ (7,186) $ (4,007) $ (15,842) $ (11,543)
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share) $ (6.43) $ (38.74) $ (18.86) $ (129.84)
Weighted average number of common shares outstanding, basic and diluted (in shares) 1,117,769 103,442 839,900 88,901